TP53 and cancer: Consequently, targeting Chk1 and Wee1 with specific inhibitors in combination with radiotherapy to induce DNA damage is considered a potentially important therapeutic strategy for treating human cancers, particularly those with p53 mutations that lack an efficient G1/S checkpoint and therefore are predictably more susceptible to this treatment.